Weill Cornell Medicine has received $4.2 million to study how the immune system in some people infected with HIV can keep the virus under control, which could lead to new therapies.
For undergraduate would-be entrepreneurs, this competition encourages examining micro- or macro-level problems and envisioning ways to fix them via innovative business ventures.
A classic psychedelic was found to activate a cell type in the brain of mice and rats that silences other neighboring neurons, providing insight into how such drugs reduce anxiety.
Weill Cornell Medicine and the Cornell Jeb E. Brooks School of Public Policy have established the Cornell Health Policy Center to serve as the locus for health policy impact, research and training across Cornell.
A new system can accurately assess the chromosomal status of in vitro-fertilized embryos using only time-lapse video images of the embryos and maternal age, according to a study from investigators at Weill Cornell Medicine.
A new consortium co-led by Weill Cornell Medicine has been awarded a five-year, $31 million grant from the NIH’s National Institute of Allergy and Infectious Diseases to accelerate the development of better treatment regimens for tuberculosis.
A new study from Weill Cornell Medicine researchers helps explain why having ApoE4 – the gene variant most closely linked to Alzheimer’s disease – increases the risk of neurodegeneration and white matter damage.
A study from Weill Cornell Medicine provides new insights into a pair of proteins and their opposing functions in regulating the interferon response in hepatic stellate cells, a critical immune component in the liver’s fight against tumors.
About half of patients with metastatic melanoma treated with a combination of immune checkpoint inhibitors survive cancer-free for 10 years or more, according to a report from Weill Cornell Medicine and Dana-Farber Cancer Center investigators.